Ingalls & Snyder LLC Dynavax Technologies Corp Transaction History

Ingalls & Snyder LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 02, 2023	SELL	$12.64 - $14.99 $316 - $374	-25 Reduced 0.25%	10,000 $148,000
Q3 2022 Oct 21, 2022	SELL	$9.93 - $17.44 $54,615 - $95,920	-5,500 Reduced 35.43%	10,025 $105,000
Q1 2022 May 09, 2022	BUY	$9.75 - $14.44 $243 - $361	25 Added 0.16%	15,525 $168,000
Q4 2021 Feb 11, 2022	BUY	$13.17 - $20.94 $39,510 - $62,820	3,000 Added 24.0%	15,500 $218,000
Q2 2021 Aug 03, 2021	BUY	$7.25 - $10.99 $90,625 - $137,375	12,500 New	12,500 $123,000
Q1 2020 Apr 22, 2020	SELL	$2.27 - $6.2 $32,915 - $89,900	-14,500 Closed	0 $0
Q3 2019 Oct 16, 2019	BUY	$2.69 - $4.85 $39,005 - $70,325	14,500 New	14,500 $52,000

288

131M

507K

374K

Ticker DVAX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 126,474,000
Market Cap $1.74B
Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...

Get notified when there are updates to the investment portfolio of Ingalls & Snyder LLC, based on Form 13F filings with the SEC.

Stay updated on Ingalls & Snyder LLC with notifications on news.